{"id":"melphalan-prednisone-and-thalidomide","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Melphalan is a nitrogen mustard alkylating agent that cross-links DNA and causes cell death. Prednisone is a corticosteroid with anti-inflammatory and immunosuppressive properties that enhances chemotherapy efficacy. Thalidomide is an immunomodulatory drug (IMiD) that enhances T-cell proliferation, increases TNF-alpha production, and has anti-angiogenic effects, working synergistically with the chemotherapy backbone.","oneSentence":"This combination uses melphalan (alkylating agent) and prednisone (corticosteroid) as backbone chemotherapy with thalidomide (immunomodulatory agent) to kill myeloma cells and enhance immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:36.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed or relapsed/refractory)"}]},"trialDetails":[{"nctId":"NCT00602641","phase":"PHASE3","title":"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-29","conditions":"Multiple Myeloma","enrollment":306},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT01063179","phase":"PHASE3","title":"Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":511},{"nctId":"NCT00907452","phase":"NA","title":"Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2009-07-29","conditions":"Myeloma","enrollment":143},{"nctId":"NCT00689936","phase":"PHASE3","title":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2008-08-21","conditions":"Multiple Myeloma","enrollment":1623},{"nctId":"NCT00232934","phase":"PHASE3","title":"Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients","status":"COMPLETED","sponsor":"Gruppo Italiano per lo Studio del Mieloma Multiplo","startDate":"2002-01","conditions":"Multiple Myeloma","enrollment":400},{"nctId":"NCT00040937","phase":"PHASE2","title":"S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2002-06","conditions":"Multiple Myeloma","enrollment":147},{"nctId":"NCT00406978","phase":"PHASE1, PHASE2","title":"Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Silvio Aime","startDate":"2006-02","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT00961467","phase":"PHASE2","title":"RMPT for Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2007-02","conditions":"Multiple Myeloma","enrollment":44},{"nctId":"NCT00507416","phase":"PHASE3","title":"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":502},{"nctId":"NCT00205751","phase":"PHASE2, PHASE3","title":"Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy","status":"COMPLETED","sponsor":"Austrian Forum Against Cancer","startDate":"2001-08","conditions":"Multiple Myeloma","enrollment":350},{"nctId":"NCT01532856","phase":"PHASE3","title":"Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years","status":"UNKNOWN","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":64},{"nctId":"NCT00652041","phase":"PHASE4","title":"Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00443235","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma More Than 65 Years Old","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2005-03","conditions":"Multiple Myeloma","enrollment":260},{"nctId":"NCT01274403","phase":"PHASE2","title":"A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Gruppo Italiano Studio Linfomi","startDate":"","conditions":"Multiple Myeloma","enrollment":130},{"nctId":"NCT00461747","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma Under 65 Years","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":390},{"nctId":"NCT00644306","phase":"PHASE3","title":"Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma","status":"TERMINATED","sponsor":"Central Hospital, Nancy, France","startDate":"2002-04","conditions":"Newly Diagnosed, Multiple Myeloma","enrollment":232},{"nctId":"NCT00358020","phase":"PHASE2","title":"Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2004-11","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT00367185","phase":"PHASE3","title":"Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2000-05","conditions":"Multiple Myeloma","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prednisone","Thalomid"],"phase":"phase_3","status":"active","brandName":"Melphalan, Prednisone and Thalidomide","genericName":"Melphalan, Prednisone and Thalidomide","companyName":"Gruppo Italiano Studio Linfomi","companyId":"gruppo-italiano-studio-linfomi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses melphalan (alkylating agent) and prednisone (corticosteroid) as backbone chemotherapy with thalidomide (immunomodulatory agent) to kill myeloma cells and enhance immune response. Used for Multiple myeloma (newly diagnosed or relapsed/refractory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}